Edward Rayner
Edward Rayner is a renowned professional in the field of healthcare innovation and data security as the Commercial Director at Blok Bioscience.
He obtained a Master of Arts (M.A.) in Chemistry from Oriel College at Oxford University, demonstrating his strong educational background in the sciences.
Rayner furthered his academic pursuits by studying MA Chemistry MSc Management at the University of Oxford, showcasing his multidisciplinary interests.
With vast experience in the industry, he has held key positions in several organizations, including Non-executive Director roles at Pharmaxis, Simbec Orion Group, and Depixus.
Edward Rayner leveraged his expertise as an Investment Director at Arix Bioscience plc, highlighting his strategic and managerial skills in the biotechnology sector.
His background includes roles such as Senior Portfolio Manager at AMP Capital and Director of Research Alliance Growth Equities at AllianceBernstein, demonstrating his financial acumen and investment prowess.
Rayner's proficiency was further evident in his former VP European Research position at Alliance Bernstein Investment, showcasing his research capabilities.
Prior to that, he served as Director of European Research at UBS Global Asset Management, specializing in Media, Leisure & Telecoms sectors, and as a Research Analyst at J.P. Morgan Investment Management.
Edward Rayner's early career included a role as a Business Analyst at MarchFIRST Enterprises, illustrating his diverse professional experiences across different industries.
His current focus at BLOK BioScience involves merging IT experts, data security specialists, and medical professionals to create innovative solutions for immunity tracking, emphasizing his commitment to cutting-edge healthcare technologies.
